EU expands approval of ALK’s house dust mite pill
European regulators have expanded the scope of ALK-Abello’s Acarizax to include the treatment of adolescent patients with house dust mite-induced allergic rhinitis.
Read More
Tag: Acarizax
- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
